Navigation Links
U-Iowa improves delivery of cancer-fighting molecules
Date:8/27/2009

Small interfering RNA (siRNA), a type of genetic material, can block potentially harmful activity in cells, such as tumor cell growth. But delivering siRNA successfully to specific cells without adversely affecting other cells has been challenging.

University of Iowa researchers have modified siRNA so that it can be injected into the bloodstream and impact targeted cells while producing fewer side effects. The findings, which were based on animal models of prostate cancer, also could make it easier to create large amounts of targeted therapeutic siRNAs for treating cancer and other diseases. The study results appeared online Aug. 23 in the journal Nature Biotechnology.

"Our goal was to make siRNA deliverable through the bloodstream and make it more specific to the genes that are over expressed in cancer," said the study's senior author Paloma Giangrande, Ph.D., assistant professor of internal medicine and a member of Holden Comprehensive Cancer Center.

In previous research completed at Duke University, Giangrande's team showed that a compound called an aptamer can be combined with siRNA to target certain genes. When the combined molecule is directly injected into tumors in animal models, it triggers the processes that stop tumor growth. However, directly injecting the combination into tumors in humans is difficult.

In the new study, the researchers trimmed the size of a prostate cancer-specific aptamer and modified the siRNA to increase its activity. Upon injection into the bloodstream, the combination triggered tumor regression without affecting normal tissues.

Making the aptamer-siRNA combination smaller makes it easier to produce large amounts of it synthetically, Giangrande said.

The team also addressed the problem that large amounts of siRNA are needed since most of it gets excreted by the kidneys before having an effect. To keep siRNA in the body longer and thereby use less of it, the team modified it using a process called PEGlyation.

"If you want to use siRNA effectively for clinical use, especially for cancer treatment, you need to deliver it through an injection into the bloodstream, reduce the amount of side effects and be able to improve its cost-effectiveness. Our findings may help make these things possible," Giangrande said.

Although the current study focused on prostate cancer, the findings could apply to other cancers and diseases. Giangrande said the next step is to test the optimized aptamer-siRNA compound in a larger animal model.


'/>"/>

Contact: Becky Soglin
becky-soglin@uiowa.edu
319-356-7127
University of Iowa
Source:Eurekalert  

Related biology news :

1. Exercise improves thinking, reduces diabetes risk in overweight children
2. Endobronchial valve significantly improves emphysema
3. Teamwork improves learning and career success
4. New clinical data shows chromium picolinate improves cognitive function
5. Stem-cell transplantation improves muscles in MD animal model, UT Southwestern researchers report
6. Herceptin and chemo improves response rates without major adverse effects in HER2 breast cancer
7. New surgery improves head and neck cancer treatment
8. More than words: childbirth training change improves safety, cuts unnecessary procedures
9. CAPHOSOL relieves oral mucositis and improves quality-of-life in cancer patients
10. JDRF-funded clinical trial demonstrates continuous glucose monitoring improves blood sugar control
11. Pictures of hot fudge sundaes arouse: Understanding emotions improves our food choices
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
U-Iowa improves delivery of cancer-fighting molecules
(Date:2/3/2016)... Vigilant Solutions announces today that the ... Missouri solved two recent hit-and-run cases with ... Vigilant Solutions. Brian Wenberg explains, "I ... was walking out of a convenience store and witnessed an elderly male back ... striking his vehicle and leaving the scene.  In his ...
(Date:2/2/2016)... , Feb. 2, 2016 Checkpoint Inhibitors ... Rising Market Are you interested in the ... revenues for checkpoint inhibitors. Visiongain,s report gives those ... product and national level. Avoid falling behind ... progress, opportunities and revenues those emerging cancer therapies ...
(Date:2/1/2016)... 2016 Rising sales of consumer ... touchfree intuitive gesture control market size ... of consumer electronics coupled with new technological advancements to ... size through 2020   --> ... technological advancements to drive global touchfree intuitive gesture control ...
Breaking Biology News(10 mins):
(Date:2/9/2016)... ... February 09, 2016 , ... With a presidential election in November and the ... will bring together over 500 top healthcare leaders for a night and day of ... organized by MBA students of the University of Pennsylvania’s Wharton School, will be held ...
(Date:2/9/2016)... of Prussia, PA (PRWEB) , ... February 09, 2016 , ... ... Business Development, Europe. Based in Paris, he will focus on acquiring new accounts ... are being met. , “Fred brings to our European clients more ...
(Date:2/9/2016)... 2016 This market research report on the ... prospects of the market in terms of revenue (USD ... in the manufacture of microbiology culture media and related ... market snapshot providing the overall information of various market ... section also provides the overall information and data analysis ...
(Date:2/8/2016)... - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today ... technology companies in the TSX Venture 50 TM . ... the TSX Venture Exchange, in each of five major industry ... & life sciences, diversified industries and technology – based on ... investment, market cap growth, trading volume and analyst coverage. All ...
Breaking Biology Technology: